In addition, both preclinical and clinical studies have shown that a dual CCR2/CCR5 antagonist, cenicriviroc (CVC), is an effective and safe antifibrotic agent for treating nonalcoholic steatohepatitis (NASH) and alcohol-induced steatohepatitis (9–12). This evidence concerns the gene CCR2 and metabolic dysfunction-associated steatohepatitis.